New insights into molecular pathways in colorectal cancer: Adiponectin, interleukin-6 and opioid signaling

Świerczyński, Mikołaj; Szymaszkiewicz, Agata; Fichna, Jakub; Zielińska, Marta

doi:10.1016/j.bbcan.2020.188460

Cited by 17 publications

(13 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The terminal differentiation of goblet cells is directly controlled by the transcription factor SAM pointed domain-containing ETS transcription factor (Spdef) (83) and also via a network of transcriptional factors regulated by the Notch, Wnt/b-catenin, PI3-kinase/Akt and bone morphogenetic protein (BMP) signaling pathways known to influence developmental and inflammation pathways (84). Studies have demonstrated that the IL-6 mediated Jak/STAT3 pathway may drive goblet cells differentiation via its downstream PI3-kinase/ Akt signal peptide corroborating the previous finding of visible damage of mucosa in IL-6 −/− mice (85,86).…”

Section: Protection Mechanisms Against Gut Inflammation-the Role Of M...supporting

confidence: 74%

“…Another defensive barrier is represented by the junctions between epithelial cells, namely, tight junction (TJ), adhesion junction (AJ), desmosomes connection, and gap junction from top to basement, (86,(91)(92)(93). The TJ present in the cardinal position is composed of occludin, claudins, junctional adhesion molecule (JAM), and zonula occludens (ZO) and limits the passage of macromolecules and microorganisms (91).…”

Section: Protection Mechanisms Against Gut Inflammation-the Role Of M...mentioning

confidence: 99%

See 1 more Smart Citation

Contribution of Epithelial and Gut Microbiome Inflammatory Biomarkers to the Improvement of Colorectal Cancer Patients’ Stratification

et al. 2022

View full text Add to dashboard Cite

In order to ensure that primary endpoints of clinical studies are attained, the patients’ stratification is an important aspect. Selection criteria include age, gender, and also specific biomarkers, such as inflammation scores. These criteria are not sufficient to achieve a straightforward selection, however, in case of multifactorial diseases, with unknown or partially identified mechanisms, occasionally including host factors, and the microbiome. In these cases, the efficacy of interventions is difficult to predict, and as a result, the selection of subjects is often random. Colorectal cancer (CRC) is a highly heterogeneous disease, with variable clinical features, outcomes, and response to therapy; the CRC onset and progress involves multiple sequential steps with accumulation of genetic alterations, namely, mutations, gene amplification, and epigenetic changes. The gut microbes, either eubiotic or dysbiotic, could influence the CRC evolution through a complex and versatile crosstalk with the intestinal and immune cells, permanently changing the tumor microenvironment. There have been significant advances in the development of personalized approaches for CRC screening, treatment, and potential prevention. Advances in molecular techniques bring new criteria for patients’ stratification—mutational analysis at the time of diagnosis to guide treatment, for example. Gut microbiome has emerged as the main trigger of gut mucosal homeostasis. This may impact cancer susceptibility through maintenance of the epithelial/mucus barrier and production of protective metabolites, such as short-chain fatty acids (SCFAs) via interactions with the hosts’ diet and metabolism. Microbiome dysbiosis leads to the enrichment of cancer-promoting bacterial populations, loss of protective populations or maintaining an inflammatory chronic state, all of which contribute to the development and progression of CRC. Meanwhile, variations in patient responses to anti-cancer immuno- and chemotherapies were also linked to inter-individual differences in intestine microbiomes. The authors aim to highlight the contribution of epithelial and gut microbiome inflammatory biomarkers in the improvement of CRC patients’ stratification towards a personalized approach of early diagnosis and treatment.

show abstract

Section: Protection Mechanisms Against Gut Inflammation-the Role Of M...supporting

confidence: 74%

Section: Protection Mechanisms Against Gut Inflammation-the Role Of M...mentioning

confidence: 99%

Contribution of Epithelial and Gut Microbiome Inflammatory Biomarkers to the Improvement of Colorectal Cancer Patients’ Stratification

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer is the frequent cancer globally and has high mortality and incidence rates ( Wieszczy et al, 2020 ; Świerczyński et al, 2021 ; Zaborowski et al, 2021 ; Zhao et al, 2021 ). Bi et al (2020) revealed that LINC01116 was highly expressed in CRC tissues compared to normal tissues, and patients with high expression of LINC01116 had a very poor prognosis.…”

Section: Expression and Clinical Characteristics Of Linc01116 In Various Cancer Typesmentioning

confidence: 99%

Promising Advances in LINC01116 Related to Cancer

Xu¹,

Yu²,

Zhang³

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are RNAs with a length of no less than 200 nucleotides that are not translated into proteins. Accumulating evidence indicates that lncRNAs are pivotal regulators of biological processes in several diseases, particularly in several malignant tumors. Long intergenic non-protein coding RNA 1116 (LINC01116) is a lncRNA, whose aberrant expression is correlated with a variety of cancers, including lung cancer, gastric cancer, colorectal cancer, glioma, and osteosarcoma. LINC01116 plays a crucial role in facilitating cell proliferation, invasion, migration, and apoptosis. In addition, numerous studies have recently suggested that LINC01116 has emerged as a novel biomarker for prognosis and therapy in malignant tumors. Consequently, we summarize the clinical significance of LINC01116 associated with biological processes in various tumors and provide a hopeful orientation to guide clinical treatment of various cancers in future studies.

show abstract

“…Much effort has been dedicated to uncovering genetic and epigenetic alterations driving the development of CRC from normal epithelial cells of intestinal mucosa into colorectal cancer cells (Markowitz & Bertagnolli, 2009 ). Environmental factors, including lifestyle, have also been implicated in CRC pathogenesis (Świerczyński et al, 2020 ); in particular, obesity and metabolic‐related disorders are strictly related to an increased risk of CRC, highlighting the functional cross‐talk existing between the adipose tissue and peripheral organs, mainly related to the hormonal function of the adipose tissue and the dysregulated production of adipokines (Karczewski et al, 2019 ). Indeed, recent studies revealed that the overexpression or loss of several adipokines and the altered expression of their receptors may lead to CRC, pointing to a role for adipokine‐receptor axis in colorectal carcinogenesis (Kawashima et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

microRNA‐377‐3p downregulates the oncosuppressor T‐cadherin in colorectal adenocarcinoma cells

Palo

Siniscalchi

Polito

et al. 2021

Cell Biology International

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second leading cause of death of malignant tumors worldwide. Recent studies point to a role for the adiponectin-receptor axis in colorectal carcinogenesis, and in particular to the oncosuppressive properties of the T-cadherin receptor. In addition, the loss of T-cadherin expression in tumor tissues has been linked to cancer progression and attributed to aberrant methylation of its promoter. Recognizing the pivotal role of microRNAs in CRC, this study explores their possible contribution to the downregulation of T-cadherin. A systematicThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

New insights into molecular pathways in colorectal cancer: Adiponectin, interleukin-6 and opioid signaling

Cited by 17 publications

References 79 publications

Contribution of Epithelial and Gut Microbiome Inflammatory Biomarkers to the Improvement of Colorectal Cancer Patients’ Stratification

Contribution of Epithelial and Gut Microbiome Inflammatory Biomarkers to the Improvement of Colorectal Cancer Patients’ Stratification

Promising Advances in LINC01116 Related to Cancer

microRNA‐377‐3p downregulates the oncosuppressor T‐cadherin in colorectal adenocarcinoma cells

Contact Info

Product

Resources

About